News

ESOP Global: Response to the new EU pharmaceutical legislation proposal (2023)


About the past and present

of ISOPP and ESOP Global (October 2023)

Question: Some colleagues have received an invitation for a virtual meeting of different nations with leadership. Where does the ISOPP get our email addresses from and what is this all about?

Klaus: Since we as ESOP operate our homepage openly for all interested parties, i.e. we allow everyone to participate in our activities free of charge, and all delegates can be contacted directly via the mailing list. The fact that the ISOPP is now showing interest in national issues in the context of oncological therapy only makes it clear that it has not missed the fact that we as ESOP Global have now brought together 70 countries and their active members for a fruitful exchange.

Question: Is this a new ISOPP strategy?

Klaus: We don’t know the decisions of the committees, but we can see the effects. When we founded the ESOP in 2000 because we thought it would be fruitful for better patient care to pass on knowledge to anyone who was interested, this was rejected by the countries, the majority of which belonged to the former Commonwealth. Since that days we propagate the goal worldwide: “Unity in diversity”

Question: Why is it that the ISOPP now wants to be open?

Klaus: There are certainly several reasons. Firstly, the ISOPP has started to organise its congresses annually rather than every two years, which puts it in strong competition with us. Especially in the years in which we organise the ECOP. The money that the industry, for example, budgets annually for advertising, including stands at congresses and satellite symposia, is limited. In this respect, the ISOPP is looking for national associations to participate in their congresses as co-organisers. On the other hand, the ISOPP also seems to have realised that the time of elitist associations is over if we not only want to support the development and use of new medicines, but also want to make knowledge available to all colleagues worldwide to support the entire treatment process. Through the EUSOP specialisation programme and the regional lectures it contains, we are not only strengthening our colleagues locally, but also our society. This also includes the ongoing and continuous development of quality standards. By already working on the 7th version, involving all experts worldwide, we are demonstrating our sustainability-orientated policy.

Question: You were the first elected president of the ISOPP in 1998. How do you feel about this unfriendly behaviour now?

Klaus: I don’t want to hide the fact that on the one hand this behaviour of long-time colleagues, such as the new ISOPP Vice President, who also participated as a delegate in the ESOP for the BOPA before BREXIT, hurts me. However, I have not given up hope of achieving fruitful cooperation in the future in the interests of patients. For this reason, on behalf of the ESOP Executive Committee, I have sent a detailed letter to the presidents of the ISOPP in which we offer a hand to reach an understanding on an equal footing, but at the same time make it a prerequisite to end the competition for finances and the organisation of the annual congress in the same year as the ECOP.


The lack of medicines is scaring people. What is the reason and how can it be countered in the long term? (December 2022)


What makes an organization strong that has dedicated itself to humanitarian goals and the activities of each individual take place unpaid in their free time? (November 2022)


One day with Oncology Pharmacy
Presented by 15 countries:


We present you the daily news from ECOP 5 (30th June to 2nd July)
>>Thursday<<
>>Friday<<
>>Saturday<<


Top